Terhi T Piltonen1, Paolo Giacobini2, Åsa Edvinsson3, Steinar Hustad4, Susanne Lager3, Laure Morin-Papunen5, Juha S Tapanainen6, Inger Sundström-Poromaa3, Riikka K Arffman5. 1. Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland. Electronic address: terhi.piltonen@oulu.fi. 2. Jean-Pierre Aubert Research Center, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Institut National de la Santé et de la Recherche Médicale, Lille, France; Fédération Hospitalière Universitaire, School of Medicine, University of Lille, Lille, France. 3. Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. 4. Department of Clinical Science, University of Bergen, Bergen, Norway; Core Facility for Metabolomics, University of Bergen, Bergen, Norway. 5. Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland. 6. Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Abstract
OBJECTIVE: To investigate plasma antimüllerian hormone (AMH) concentration and its relation to steroid hormone levels in pregnant women with polycystic ovary syndrome (PCOS) and controls at term. DESIGN: Case-control study. SETTING: University-affiliated hospital. PATIENT(S): A total of 74 pregnant women at term: 25 women with PCOS (aged 31.6 ± 3.9 years [mean ± standard deviation], body mass index 24.0 ± 3.9 kg/m2, mean gestational length 279 ± 9 days) and 49 controls (aged 31.7 ± 3.3 years, body mass index 24.0 ± 3.3 kg/m2, mean gestational length 281 ± 9 days). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Plasma AMH and steroid hormone levels. RESULT(S): Antimüllerian hormone, T, and androstenedione levels were higher in women with PCOS at term compared with controls, whereas estrogen and P levels were similar. The differences were pronounced in women carrying a female fetus. Testosterone and AMH levels correlated positively in both groups, but E2 levels only in women with PCOS. CONCLUSION(S): Pregnant women with PCOS present with elevated AMH and androgen levels even at term, suggesting a hormonal imbalance during PCOS pregnancy. Differences were detected especially in pregnancies with a female fetus, raising the question of whether female pregnancies are more susceptible to AMH and steroid hormone actions.
OBJECTIVE: To investigate plasma antimüllerian hormone (AMH) concentration and its relation to steroid hormone levels in pregnant women with polycystic ovary syndrome (PCOS) and controls at term. DESIGN: Case-control study. SETTING: University-affiliated hospital. PATIENT(S): A total of 74 pregnant women at term: 25 women with PCOS (aged 31.6 ± 3.9 years [mean ± standard deviation], body mass index 24.0 ± 3.9 kg/m2, mean gestational length 279 ± 9 days) and 49 controls (aged 31.7 ± 3.3 years, body mass index 24.0 ± 3.3 kg/m2, mean gestational length 281 ± 9 days). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Plasma AMH and steroid hormone levels. RESULT(S): Antimüllerian hormone, T, and androstenedione levels were higher in women with PCOS at term compared with controls, whereas estrogen and P levels were similar. The differences were pronounced in women carrying a female fetus. Testosterone and AMH levels correlated positively in both groups, but E2 levels only in women with PCOS. CONCLUSION(S): Pregnant women with PCOS present with elevated AMH and androgen levels even at term, suggesting a hormonal imbalance during PCOS pregnancy. Differences were detected especially in pregnancies with a female fetus, raising the question of whether female pregnancies are more susceptible to AMH and steroid hormone actions.
Authors: Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott Journal: Endocr Rev Date: 2020-07-01 Impact factor: 19.871
Authors: Emily V Ho; Chengxian Shi; Jessica Cassin; Michelle Y He; Ryan D Nguyen; Genevieve E Ryan; Karen J Tonsfeldt; Pamela L Mellon Journal: Endocrinology Date: 2021-12-01 Impact factor: 5.051
Authors: Christopher R McCartney; Rebecca E Campbell; John C Marshall; Suzanne M Moenter Journal: J Neuroendocrinol Date: 2022-01-26 Impact factor: 3.870
Authors: Régine P M Steegers-Theunissen; Rosalieke E Wiegel; Pauline W Jansen; Joop S E Laven; Kevin D Sinclair Journal: Int J Mol Sci Date: 2020-11-03 Impact factor: 5.923